Antimicrobial Agent, Cephalosporins, Drug Resistance
Conditions
Keywords
Ceftobiprole, ZEVTERA, ZEFTERA, Intestinal Microflora
Brief summary
The purpose of the study is to investigate the effect of ceftobiprole treatment on intestinal microflora in healthy volunteers.
Detailed description
This is an open-label, single center study to investigate the effect on human intestinal microflora of multiple doses of ceftobiprole treatment administered at 8 hours intervals for 7 consecutive days. Careful investigation of the effect of Ceftobiprole treatment on the intestinal microflora is of importance since alteration of the intestinal microflora balance may facilitate colonization by pathogenic bacteria strains or enable microorganisms already present in the normal microflora to develop resistance. A total of 7 fecal samples will be collected on day 2, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in fecal, intestinal microflora pattern and measuring the susceptibility for Ceftobiprole of isolated bacterial strains. A total of 13 plasma samples will be collected on day 1, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in plasma. Safety evaluations including physical examination, vital signs, clinical laboratory tests, electrocardiogram and adverse event monitoring will be performed throughout the study. 500 mg ceftobiprole, intravenous infusion over 120 minutes, every 8 hours for 7 consecutive days
Interventions
DRUGCeftobiprole
ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
Sponsors
Basilea Pharmaceutica
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
\- Healthy volunteers with body weight \>= 50 kg and body mass index between 18 and 30 * Agree to remain hospitalized at the trial unit during the 7-day drug administration period and will only leave the trial unit under supervision of a study nurse twice a day for one hour maximum * Refrain from excessive jogging and any strenuous exercise during the study * Be able to adhere to the dietary, fluid and smoking restrictions during the study * Have negative pregnancy test result at the screening and agree to use adequate contraception method and not to become pregnant or donate sperm throughout the study
Exclusion criteria
* No clinically significant medical illness, abnormal findings in physical examination, vital signs, laboratory tests and electrocardiogram, or known allergy to the study drug, cephalosporins, beta-lactam antibiotics or other clinically significant allergies requiring treatment * No antibiotic treatment within the last 3 months * No drug or alcohol abuse within the last 5 years * No blood donation or substantial loss of blood of more than 500 ml within the last 3 months or intention to donate blood during the study or within 1 month after study completion * No history of smoking of more than 10 cigarettes , or 2 cigars, or 2 pipes of tobacco or 5 sniffs per day within the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bacterial strains and numbers in feces; Minimum inhibitory concentrations for ceftobiprole for isolated resistant strains | Day 2, 4, 7, 10, 14 and 21 |
Secondary
| Measure | Time frame |
|---|---|
| Fecal concentration of ceftobiprole | Day 2, 4, 7, 10, 14 and 21 |
| Plasma Concentration of ceftobiprole | Day 1, 4, 7, 10, 14, and 21 |
Outcome results
None listed